Vincent Michael Figueredo, MD, FACC, FAHA
Vincent Michael Figueredo, MD, FACC, FAHA Cardiology Division, Albert Einstein Medical Center Present Appointments 1/07 Director, Cardiovascular Diseases Fellowship Programs, Albert Einstein Medical Center, Phil., PA 6/06 Associate Professor of Medicine, Jefferson Medical College, Philadelphia, PA 7/05 Faculty, Cardiology Division, Albert Einstein Medical Center, Philadelphia, PA 4/07 Associate, Center for Urban Health Policy and Research, Philadelphia, PA 10/09 Director, Cardiac Rehabilitation Program, Albert Einstein Medical Center, Philadelphia, PA Past Appointments 7/05-12/06 Medical Director, Cardiac Imaging of Northeast Philadelphia, PA 7/05-12/06 Faculty, Department of Medicine, Frankford Hosp., Jefferson Health System, Phil., PA 7/05-12/06 Medical Staff, Nazareth Hospital, Philadelphia, PA 7/05-12/06 Member, Greater Philadelphia Cardiology Associates, Philadelphia, PA 8/03-6/05 Chair, Cardiology & Cardiothoracic Surgery Department, Lovelace Health Systems, NM 1/01-6/05 Clinical Associate Professor of Medicine, Univ. of New Mexico Health Sciences Center 11/00-6/05 Director, Lipid Management Program, Heart & Vascular Center, Lovelace Clinic, NM 7/98-6/05 Director, Echocardiography Lab (ICAEL accredited), Lovelace Health Systems, NM 7/98-6/05 Director, Clinical Research, Heart & Vascular Center, Lovelace Health Systems, NM 7/98-1/01 Clinical Assistant Professor of Medicine, Univ of New Mexico Health Sciences Center 7/96-6/98 Affiliated Member, Ernest Gallo Clinic and Research Center, SF, CA 7/96-6/98 Director, Echocardiography Laboratory, San Francisco General Hospital 7/96-6/98 Faculty Investigator, San Francisco Injury Center at SF General Hospital 7/94-6/98 Assistant Professor of Medicine in Residence, Univ. of California, San Francisco 7/94-6/98 Attending Physician, Dept. of Medicine (Cardiology), SF General Hospital 7/94-6/98 Attending Physician, Dept. of Medicine (Cardiology), SF VA Hospital Postgraduate Training 7/92-6/94 Clinical Fellow in Cardiology; University of California, San Francisco, CA 7/90-6/92 Research Fellow; Cardiovascular Research Institute, UCSF, San Francisco, CA 6/87-6/90 Resident and Intern, Internal Medicine; Columbia Presbyterian Medical Center, NY Education 7/83-5/87 8/79-6/83 M.D.; College of Physicians & Surgeons, Columbia University, New York, NY B.A.; Chemistry; Haverford College, Haverford, PA Professional Qualifications Medical Licenses: CA G068066; NM 98-55; NY 177224; PA MD426336 Diplomat, National Board of Medical Examiners: 7/1/1988 Diplomat, American Board of Internal Medicine: 9/12/1990 Diplomat, ABIM, Cardiovascular Disease Subspecialty: 11/8/1995; recertification 11/7/2005 Board Certified Specialist in Clinical Hypertension, American Society of Hypertension: 8/9/2001 Diplomat, Certification Board of Nuclear Cardiology: 10/25/2006 Diplomat, Adult Comprehensive Echocardiography, National Board of Echocardiography: 6/30/07 Figueredo, V.M. Society Memberships Fellow, American College of Cardiology Fellow, American Heart Association Fellow, American Society of Echocardiography Board Member, Delaware Valley Echo Society (American Society of Echocardiography Chapter) Board Member, Nuclear Cardiology Working Group of the Delaware Valley (American Society of Nuclear Cardiology Chapter) Philadelphia Lipid and Atherosclerosis Club Northeast Lipid Association (Chapter of the National Lipid Association) Research Grants and Scholarships 1982 IBM Corporation, Student Research Scholarship Award 1990-1992 NIH, National Research Scholarship Award 1992-1993 Medical School Grant, Merck & Company 1994-1995 University of California, Faculty Development Award 1994-1996 American Heart Association, California Affiliate, Grant-in-Aid 1994-1999 NIH, Clinical Investigator Development Award 1996-1998 American Beverage Medical Research Foundation Grant 1996-2001 NIH, RO1 AA 11135-01 1998-2000 Int'l Collaboration Grant-in-aid for Scientific Research, Ministry of Education of Japan 2000-2001 Grant-in-Aid for Scientific Research, Ministry of Education of Japan 2002-2004 Int'l Collaboration Grant-in-aid for Scientific Research, Ministry of Education of Japan 2004-2006 Grant-in-Aid for Scientific Research, Ministry of Education of Japan (co-investigator) 2006-2007 Grant-in-Aid for Scientific Research, 18592210, Ministry of Education, Culture, Sports, Science and Technology of Japan (co-investigator) 2007-2009 Pennsylvania Department of Health Commonwealth Universal Research Enhancement (C.U.R.E.). Program. “Exercise, Metabolic & Inflammatory Processes in Postmenopausal Minority Women” (consultant). 2008-2009 CV Therapeutics. “Effects of Ranolazine on Diastolic Function in Angina Patients”. (principal investigator) 2008-2010 Pennsylvania Department of Health Commonwealth Universal Research Enhancement (C.U.R.E.) Program. “Feasibility of Adopting the Mediterranean Diet to Modify Risk factors Associated with Metabolic Syndrome in Older African American Women” (coprincipal investigator) 2008-2009 Awarded by the Albert Einstein Society, Philadelphia, PA. Supplemental funds for “Feasibility of Adopting the Mediterranean Diet to Modify Risk factors Associated with Metabolic Syndrome in Older African American Women” (co-principal investigator) 2008-2011 Grant-in-Aid for Scientific Research, Ministry of Education, Culture, Sports, Science and Technology of Japan (co-investigator) 2009-2010 Pennsylvania Department of Health Commonwealth Universal Research Enhancement (C.U.R.E.) Program. “The Use of Telephone Support to Modify Risk Factors Associated with Metabolic Syndrome Using the Mediterranean Diet in Older African American Women” (co-principal investigator) 2009-2010 Einstein Society Grant. "Incidence, Characteristics and Prognosis of Transient Myocardial Dysfunction in Critically Ill Patients.” (principal investigator) Patents System for Transmitting Video Images Over a Computer Network to a Remote Receiver. Inventors: VM Figueredo, KA Roman, PR Raposa, RS Neale, CJ Hoomani, TJ Broadbent. U.S. Patent 7,257,158. 2 Figueredo, V.M. Teaching Activities UCSF Dept. of Medicine Core Curriculum Series for Housestaff UCSF Dept. of Medicine, Primary Care Intern Lecture Series UCSF Dept. of Medicine Core Curriculum Series for Cardiology Fellows UCSF Medicine 110; Family and Community Medicine Lecture Series UCSF Medicine 132a; Introduction to Clinical Medicine UCSF Medicine 140.22; Pathophysiology of Disease-Clinical Pharmacology and Therapeutics UCSF Medicine 140.35; Cardiology Consultation UCSF Medicine 140; Medicine Ward Service-Cardiology UCSF Dept. of Medicine Core Curriculum for Primary Care Housestaff UCSF Dept. of Medicine Core Curriculum for Medical Housestaff UCSF Medicine 111; Mechanisms of Disease UNM Cardiology Journal Club UNM Cardiology Fellows Conference Series UNM Cardiology Graphics Conference Series UNM Internal Medicine Residents Core Curriculum Series UNM Continuity Clinic Phase II Medical Student Preceptorships Lovelace Clinic Foundation Medical Education Division Faculty Member Menaul High School Preceptorship Program Attending, Medicine Team D, Frankford-Torresdale Hospital, Jefferson Medical System Philadelphia College of Osteopathic Medicine, Medicine Preceptorships AEMC Cardiology Fellowship Conference Curriculum, Director AEMC Internal Medicine Residents Morning Report AEMC Internal Medicine Core Curriculum Series Experience Day, Germantown Friends School 9th Grade AEMC Internal Medicine Journal Club Recognition Lovelace Clinic Foundation Excellence in Education Award 2002 Frankford Hospitals, Jefferson Health System, Dedication to Teaching Award 2006 Philadelphia College of Osteopathic Medicine, Outstanding Contribution Award 2006/2007 Einstein Leadership Development Program 2009-2010 University and Public Service, Committees Pharmacy and Therapeutics Committee, San Francisco Department of Public Health 1995 San Francisco Injury Center Advisory Committee, 1996, 1997 SFGH Multidisciplinary Procedures Task Force 1997 SFGH Formulary Review Subcommittee 1997 Guest Speaker, Cardiac Health Symposium, California Pacific Medical Center, S.F., 1998 Member, Continuing Medical Education Advisory Committee, Lovelace Health Systems, 2000 Member, Physician Information Systems Advisory Group, Lovelace Health Systems, 2000 Speaker, Lovelace Health Systems Community Seminar, The Ins and Outs of Heart Disease, 2000 Member, Billing Steering Committee, Lovelace Health Systems, 2000 Member, Pharmacy and Therapeutics Committee, Lovelace Health Systems, 2000 Board Member, Medical Advisory Board, American Heart Association, Pacific Mountain Affiliate, 2001 Co-Director, New Mexico Hypertension Journal Club, 1999-2001 Pharmacy and Therapeutics Committee, Lovelace Health Systems 2000-2002 Panel Member, “Hard Facts About Women and Heart Disease”, Lovelace Women’s Health Services and the Spirit of Women “Day for You”, 2002 3 Figueredo, V.M. Author, “Lower cholesterol levels urged for older adults”, Mature Life in New Mexico Section, Albuquerque Journal, June 2002 Author, “Hormone Replacement Therapy and Heart Disease”, Mature Life in New Mexico Section, Albuquerque Journal, December 2002 Board of Governors, Lovelace Clinic Foundation 2003 Panel Member, “Pour Your Heart into it: Preventing and Managing Heart Disease From the Corporate to the Hospital Setting”, presented by Lovelace Clinic Foundation, April 2003 Member, Disease Management Program, Lovelace Health Systems, 2003 Member, Physician Planning Council, Lovelace Sandia Health Systems, 2004 Member, Lovelace Medical Center Community Advisory Board, 2005 Albert Einstein Medical Center Curriculum Committee, 2007-2008 Albert Einstein Medical Center Clinical Competency Committee, 2007-2008 Judge, Albert Einstein Medical Center Intern Research Competition, 2007 Albert Einstein Medical Center Academic Issues Committee, 2007-2008 Albert Einstein Medical Center Faculty Advisor for Housestaff, 2007-2008 Albert Einstein Medical Center Housestaff Selection Committee, 2007-2008 Chair, Education/Quality of Care/Guidelines Committee, Pennsylvania Chapter, American College of Cardiology, 2007-2008 Executive Committee, Pennsylvania Chapter, American College of Cardiology, 2007-2008 Albert Einstein Medical Center Cardiology Strategic Planning Committee, 2007-2008 Albert Einstein Medical Center Cardiology Steering Committee, 2007-2010 Chair, CCA Planning Committee, Pennsylvania Chapter, American College of Cardiology, 2008-2009 Chapter Meeting Planning Committee, PA Chapter, American College of Cardiology, 2008-2009 Nominating Committee, PA Chapter, American College of Cardiology, 2008-2009 Chair, Education Committee, Pennsylvania Chapter, American College of Cardiology, 2009-2010 Albert Einstein Medical Center Cardiology IS Steering Committee, 2009-2010 Jefferson Medical College Curriculum Committee Electives Working Group 2010 Editor, Pennsylvania Chapter American College of Cardiology Newsletter, 2010 Invited Lectures and Visiting Professorships Dept. of Cardiology Seminar Series, San Francisco General Hospital, CA, 1994 Cardiology Grand Rounds, University of California, SF, CA, 1995 Medical Grand Rounds, San Francisco General Hospital, CA, 1995 Cardiology Grand Rounds, San Francisco VA Medical Center, SF, CA, 1995 Dept. of Cardiology Seminar Series, San Francisco General Hospital, CA, 1995 Medical Grand Rounds, San Francisco VA Medical Center, SF, CA, 1996 Dept. of Cardiology Seminar Series, San Francisco General Hospital, CA, 1996 Medical Grand Rounds, San Francisco General Hospital, CA, 1996 Cardiology Grand Rounds, San Francisco VA Medical Center, SF, CA, 1996 Medical Grand Rounds, Summit Hospital, Oakland, CA, 1997 Medical Grand Rounds, Santa Theresa Community Hospital, 1997 Medical Grand Rounds, Community Hospital of Monterey Peninsula, 04/1997 Horizons Lecture Series for UCSF Medical Students, 1997 Medical Grand Rounds, Community Hospital of Monterey Peninsula, 07/1997 NIAAA/RSA Scientific Meeting with Wine Institute, San Francisco, CA, 1997 Departments of Physiology and Biophysics Seminar, Univ. of Illinois, Chicago, IL 1997 Cardiology Grand Rounds, RUSH-Presbyterian Medical Center, Chicago, IL, 1997 Cardiology Grand Rounds, Loyola University Medical Center, Chicago, IL, 1997 Medical Grand Rounds, Michael Reese Medical Center, Chicago, IL, 1997 Medical Grand Rounds, San Francisco General Hospital, CA, 1997 4 Figueredo, V.M. Cardiology Grand Rounds, San Francisco VA Medical Center, SF, CA, 1997 Nephrology Grand Rounds, Christ Hospital, Oak Lawn, IL, 1998 General Medicine Grand Rounds, Holy Cross Hospital, Chicago, IL, 1998 Medical Grand Rounds, Dameron Hospital Stockton, CA, 1998 Medical Grand Rounds, Memorial Hospital of Sheridan County, WO, 1998 Medical Grand Rounds, Univ. of New Mexico Health Sciences Center, Albuquerque, NM, 1998 Medical Grand Rounds, Washington Hospital, Freemont, CA, 1998 Medical Grand Rounds, Gila Medical Center, Silver City, NM, 1999 Medical Grand Rounds, Lakewood Regional Medical Center, Lakewood, CA, 1999 Medical Grand Rounds, Eastern New Mexico Medical Center, Roswell, NM, 1999 Cardiology Mentoring Program, Ingalls Hospital, Harvey, IL, 1999 Medical Grand Rounds, Lamb Healthcare Center, Littlefield, TX, 1999 Internal Medicine Resident Teaching Conf, Texas Tech Health Sciences Center, Lubbock, TX, 1999 Continuing Medical Education Program, Northern Navajo Medical Center, Shiprock, NM, 1999 Medical Grand Rounds, Lankenau Hospital, Lankenau, PA, 1999 Pottawatomie County Medical Society Annual Meeting, Shawnee, OK, 1999 Medical Grand Rounds, Mendocino Coast District Hospital, Ft. Bragg, CA, 1999 Medical Grand Rounds, San Juan Regional Medical Center, Farmington, NM, 1999 Medical Grand Rounds, Maricopa Medical Center, Phoenix, AZ, 1999 Grand Rounds, Lankenau Hospital, Lankenau, PA, 2000 Medical Grand Rounds, Gila Medical Center, Silver City, NM, 2000 Annual Faculty Meeting, Holy Cross Medical Group, Ft. Lauderdale, FL, 2000 Medical Grand Rounds, Kirtland 377th Medical Group, Albuquerque, NM, 2000 Medical Grand Rounds, Mt. Diablo Medical Center, Concord, CA, 2001 Medical Grand Rounds, St. Mary's Hospital, Grand Junction, CO, 2001 Medical Grand Rounds, John Muir/Mt. Diablo Medical Center, Walnut Creek, CA, 2001 Medical Grand Rounds, Kirtland 377th Medical Group, Albuquerque, NM, 2001 Medical Grand Rounds, Granada Hills Community Hospital, Granada Hills, CA, 2001 Medical Grand Rounds, Univ. of New Mexico Health Sciences Center, Albuquerque, NM, 2001 Journal Center Best Practice Grand Rounds, Lovelace Clinic, Albuquerque, NM, 2001 Speaker, Lovelace Health Systems Clinical Update CME Program, Albuquerque, NM, 2002 Guest Speaker, New Mexico Pharmaceutical Association Annual Meeting, Albuquerque, NM 2002 Speaker, Lovelace Clinic Foundation Regional CME Program, Albuquerque, NM 2002 Medical Grand Rounds, Los Alamos Medical Center, NM, 2003 Medical Grand Rounds, Albuquerque Veterans Administration Medical Center, NM, 2003 Family Medicine Grand Rounds, Univ. of New Mexico Health Sciences Center, Albuquerque, 2003 Speaker, Lovelace Health Systems Primary Care Symposium, Albuquerque, NM, 2003 Cardiology Grand Rounds, Albert Einstein Medical Center, Philadelphia, PA, 2005 Cardiology Grand Rounds, Paoli Hospital, Paoli, PA, 2005 Frankford Hospitals Grand Rounds, Philadelphia, PA 2006 Medical Grand Rounds, Albert Einstein Medical Center, Philadelphia, PA, 2006 Cardiology Grand Rounds, Albert Einstein Medical Center, Philadelphia, PA, 2007 Medical Grand Rounds, Albert Einstein Medical Center, Philadelphia, PA, 2008 Cardiology Grand Rounds, Albert Einstein Medical Center, Philadelphia, PA, 2008 Psychiatry Grand Rounds, Albert Einstein Medical Center, Philadelphia, PA, 2008 Cardiology Grand Round, Temple University Medical Center, Philadelphia, PA 2008 Cardiology Grand Round, Lankenau Medical Center, Philadelphia, PA 2009 Cardiology Grand Rounds, Albert Einstein Medical Center, Philadelphia, PA, 2010 5 Figueredo, V.M. Meeting Faculty Member Annual Advances in Heart Disease, American College of Cardiology, SF, CA, 1994 Annual Advances in Heart Disease, American College of Cardiology, SF, CA, 1996 Annual Advances in Heart Disease, American College of Cardiology, SF, CA, 1997 27th Int’l Medical Advisory Group Conf. on Alcohol Research, Vancouver, Canada, 1998 15th Winter Medical Symposium, NM Osteopathic Medical Assoc., Taos, NM, 1999 Update in Primary Care, NM Hispanic Medical Assoc., Albuquerque, NM, 1999 Annual Advances in Heart Disease, American College of Cardiology, SF, CA, 1999 Texas Pharmacy Association Continuing Education Meeting, El Paso, TX 2000 Update in Primary Care, NM Hispanic Medical Assoc., Albuquerque, NM, 2000 21st Annual Southwest Association of Hispanic American Physicians Medical Education Congress, El Paso, TX 2000 Second Annual New & Current Therapies in Heart and Vascular Care, ABQ, NM, 2001 Third Annual New & Current Therapies in Heart and Vascular Care, ABQ, NM, 2002 Update in Primary Care, NM Hispanic Medical Assoc., Albuquerque, NM, 2002 Fourth Annual New & Current Therapies in Heart and Vascular Care, ABQ, NM, 2003 New Mexico Primary Care Symposium, Santa Fe, NM, 2003 New Mexico Osteopathic Medical Assoc., 23rd Annual Balloon Fiesta Medical Symposium, Albuquerque, NM, 2003 Fifth Annual New & Current Therapies in Heart and Vascular Care, ABQ, NM, 2004 Advanced Preceptorship in the Management of Anticoagulation Therapy and Clinical Thrombosis, Albuquerque, NM, 2004 Fifth World Congress on Stress, London, England 2004 Sixth Annual New & Current Therapies in Heart and Vascular Care, ABQ, NM, 2005 Advanced Preceptorship in the Management of Anticoagulation Therapy and Clinical Thrombosis, Albuquerque, NM, 2005 Sixth World Congress on Stress, Vienna, Austria, 2007 Pennsylvania Academy of Family Physicians, Clinical Education Series, Skytop, PA 2009 Pennsylvania ACC Cardiac Care Associates Educational Conference, Hershey, PA May 1, 2009 American College of Cardiology Pennsylvania Chapter 2009 Annual Scientific Meeting, Skytop, PA, October 2-4, 2009 EuroEcho, European Society of Cardiology, Madrid, Spain, December 9-12, 2009 Pennsylvania ACC Cardiac Care Associates Educational Conference, Hershey, PA April 30, 2010 Pennsylvania ACC Cardiac Care Associates Educational Conference, Pittsburgh, PA May 14, 2010 Grant Reviewer Biomedical Research Review Subcommittee, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 2/99 & 11/99. Abstract Reviewer American College of Cardiology’s 59th Annual Scientific Session, 2010. Coordinating Editor Practical Reviews Cardiology, Oakstone Medical Publishing 2009-present. Manuscript Reviewer Alcoholism Clinical and Experimental Research American Journal of Medicine American Journal of Physiology Annals of Internal Medicine 6 Figueredo, V.M. Basic Research in Cardiology Cardiovascular Drugs and Therapeutics Echocardiography International Journal of Cardiology Lancet Journal of the American College of Cardiology Journal of Molecular and Cellular Cardiology Stress and Health: Journal of the International Society for the Investigation of Stress 7 Figueredo, V.M. BIBLIOGRAPHY Publications 1. Figueredo VM and Neu HC: Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis. J Antimicrob Chemo 1988;22:41-50. 2. Chin NX, Figueredo VM, Novelli A, and Neu HC: In vitro activity of temafloxacin, a new difluoroquinolone antimicrobial agent. Eur J Clin Microbiol 1988;7:58-63. 3. Figueredo VM, Dresdner KP, Wolney AC, and Keller AM: Postischaemic reperfusion injury in the isolated rat heart: effect of ruthenium red. Cardiovasc Res 1991;25:337-342. 4. Brandes R, Figueredo VM, Camacho SA, Massie BM, and Weiner MW: Suppression of motion artifacts in fluorescence spectroscopy of perfused hearts. Am J Physiol 1992;263(Heart Circ Physiol):H972-H980. 5. Figueredo VM, Brandes R, Weiner MW, Massie BM, and Camacho SA: Cardiac contractile dysfunction during mild coronary flow reductions is due to an altered calcium-pressure relationship in rat hearts. J Clin Invest 1992;90:1794-1802. 6. Camacho SA, Figueredo VM, Brandes R, and Weiner MW: Ca2+-dependent fluorescence transients and phosphate metabolism during low-flow ischemia in perfused hearts. Am J Physiol 1993; 268(Heart Circ Physiol): H114-H122. 7. Brandes R, Figueredo VM, Camacho SA, Baker AJ, and Weiner MW: I. Quantitation of cytosolic [Ca2+] in whole perfused rat hearts using Indo-1 fluorometry. Biophys J 1993;65:1973-1982. 8. Brandes R, Figueredo VM, Camacho SA, Baker AJ, and Weiner MW: II. Investigation of factors affecting fluorometric quantitation of cytosolic [Ca2+] in perfused hearts. Biophys J 1993;65:19831993. 9. Figueredo VM, Brandes R, Weiner MW, Massie BM, and Camacho SA: Endocardial versus epicardial differences of intracellular free calcium under normal and ischemic conditions in perfused rat hearts. Circ Res 1993; 72:1082-1090. 10. Brandes R, Figueredo VM, Camacho SA, and Weiner MW: Compensation for changes in tissue light absorption in fluoremetry of hypoxic perfused rat hearts. Am J Physiol 1994;266:H2554-H2567. 11. Camacho SA, Brandes R, Figueredo VM, and Weiner MW: Ca2+ transient decline and myocardial relaxation are slowed during low-flow ischemia in rat hearts. J Clin Invest 1994;93:951-957. 12. Schreur JH, Figueredo VM, Shames DM, and Camacho SA: Cytosolic [Ca2+] transients from whole hearts using indo-1 AM: correction for non-cytosolic fluorescence. Biophys J 1996;70:25712580. 13. Miyamae M, Camacho SA, Weiner MW, and Figueredo VM: Attenuation of postischemic reperfusion injury is related to prevention of mitochondrial Ca2+, not cytosolic Ca2+, overload in rat heart. Am J Physiol 1996;271:H2145-H2153. 14. Miyamae M, Camacho SA, Weiner MW, Diamond I, and Figueredo VM: Regular alcohol consumption mimics cardiac preconditioning by protecting against ischemia-reperfusion injury. Proc Nat Acad Sci USA 1997;94:3235-3239. 15. Miyamae M, Camacho SA, Rooney WD, Modin G, Chang KC, Weiner MW, and Figueredo VM: Inorganic phosphate and coronary perfusion pressure contribute equally to contractile dysfunction during graded ischemia in rat heart. Am J Physiol 1997; 42(2):H566-H582. 16. Chang KC, Figueredo VM, Schreur JHM, Kariya K, Weiner MW, Simpson PC, Camacho SA: Thyroid hormone reverses slowing of myocardial relaxation induced by pressure-overload hypertrophy: relationship to changes of Ca2+ handling and expression of sarcoplasmic reticulum Ca2+-ATPase and myosin heavy chain in rats. J Clin Invest 1997;100(7):1742-1749. 17. Figueredo VM, Chang KC, Baker AJ, Camacho SA: Chronic alcohol - induced changes of cardiac contractility are not due to changes in the cytosolic Ca2+ transient. Am J Physiol 1998;275(Heart Circ Physiol 44):H122-H130. 8 Figueredo, V.M. 18. Miyamae M, Camacho SA, Baker AJ, Zhong HZ, Weiner MW, Diamond I, and Figueredo VM: Alcohol consumption reduces ischemia-reperfusion injury by species-specific signaling in guinea pig and rat. Am J Physiol 1998;275(Heart Circ Physiol 44):H50-H56. 19. Baker AJ, Figueredo VM, Keung EC, and Camacho SA: Ca2+ regulates the kinetics of tension development in intact cardiac muscle. Am J Physiol 1998;275(3 Pt 2):H744-750. 20. Ho RT, Nanevicz T, Yee R, Figueredo VM. Benzocaine induced methemoglobinemia – two case reports related to transesophageal echocardiography medication. Cardiovasc Drug Therapy 1998;12(3):311-312. 21. Tian R, Halow JH, Meyer M, Dillman WH, Figueredo VM, Ingwall JS, Camacho SA: Thermodynamic limitation for Ca2+ handling contributes to decreased contractile reserve in rat hearts. Am J Physiol 1998;275(6 Pt 2):H2064-2071. 22. Miyamae M, Rodriguez MM, Camacho SA, Diamond I, Mochly-Rosen D, Figueredo VM: Activation of epsilon protein kinase C correlates with a cardioprotective effect of moderate ethanol consumption. Proc Nat Acad Sci 1998;95:8262-8267. 23. Rozycki GS, Feliciano DV, Oschner MG, Knudson MM, Hoyt DB, Davis F, Hammerman D, Figueredo V, Harviel JD, Han DC, Schmidt JA: The role of ultrasound in patients with possible penetrating cardiac wounds: A prospective multicenter study. J Trauma 1999;46(4):543-551. 24. Figueredo VM, Diamond I, Zhou H-Z, Camacho SA: Chronic dipyridamole therapy produces sustained protection against cardiac ischemia-reperfusion injury. Am J Physiol 1999:277(Heart Circ Physiol 46):H2091-H2097. 25. Halow JH, Figueredo VM, Shames DM, Camacho SA, Baker AJ: Role of slowed Ca2+ transient decline in slowed relaxation during myocardial ischemia. J Mol Cell Cardiol 1999 Sep;31(9):1739-48. 26. Wang L, Cherednichenko G, Hernandez L, Halow J, Camacho SA, Figueredo V, Schaefer S. Preconditioning limits mitochondrial Ca(2+) during ischemia in rat hearts: role of K(ATP) channels. Am J Physiol Heart Circ Physiol. 2001 May;280(5):H2321-H2328. 27. Pharr JR, West MB, Kusumoto FM, Figueredo VM: Prominent crista terminalis appearing as a right atrial mass on transthoracic echocardiogram. J Am Soc Echocardiogr 2002;15:753-755. 28. Pharr JR, Figueredo VM: Lipomatous hypertrophy of the atrial septum and prominent crista terminalis appearing as a right atrial mass. Euro J Echocardiogr 2002;3(2):159-161. 29. Miyamae M, Fujiwara H, Tanaka M, Yokota R, Takemura G, Itoh S, Domae N, Figueredo VM: Oxygen radicals mediate metabolic and ultrastructural protection of preconditioning in vivo in pig hearts. Exp Clin Cardiol 2003;7(4):173-178. 30. Miyamae M, Domae N, Zhou H-Z, Sugioka S, Diamond I, Figueredo VM: Phospholipase C Activation is required for cardioprotection by ethanol consumption. Exp Clin Cardiol 2003;8(4):184188. 31. Jaffe W and Figueredo VM: An example of Lambl’s excrescences by transesophageal echocardiogram: A commonly misinterpreted lesion. Echocardiography 2007;24(10):1086-1089. 32. Kaneda K, Miyamae M, Sugioka S, Okusa C, Inamura Y, Domae N, Kotani J, Figueredo VM: Sevoflurane enhances ethanol-induced cardiac preconditioning through modulation of nitric oxide synthase, protein kinase C and mitochondrial KATP channels in Guinea pig hearts. Anesth Analg 2008; 106:9-16. 33. Maraj S, Pressman G, Figueredo VM: Primary cardiac tumors. Int J Cardiol. 2009;133(2):152-6. 34. Dhar D, Pressman G, Subramanian S, Kaul S, Gollamudi S, Bloom E, and Figueredo VM: Natriuetric peptides and their role in heart failure in the setting of chronic renal disease: a review of current evidence. Postgrad Med J 2009:85(1004):299-302. 35. Mehta S, Parameswaran AC, Greenspan, A. Figueredo VM. Hypercalcemia due to rhabdomyolysis mimicking Brugada syndrome. Pacing Clin Electrophysiol 2009;32(11):e14-5. 9 Figueredo, V.M. 36. Okusa C, Miyamae M, Sugioka S, Kaneda K, Inamura Y, Onishi A, Domae N, Kotani J, Figueredo VM. Acute memory phase of sevoflurane preconditioning is associated with sustained translocation of PKC-α and ε, but not δ, in isolated guinea pig hearts. Eur J Anaesthesiol 2009;26(7):582-8. 37. Figueredo VM and Pressman GS. Development of an intra-operative left atrial thrombus? J Am Coll Cardiol 2009 Aug 4;54(6):e1. 38. Chunhamaneewat N, Maraj S, Borate U, Figueredo VM. A 28-year old woman with headache, blurred vision and splinter hemorrhages Am J Med Sci 2009;338(6):493. 39. Pressman GS, Crudu V, Parameswaran-Chandrika A, Romero-Corral A, Purushottam B, Figueredo VM. Can total cardiac calcium predict the coronary calcium score? Int J Cardiol. 2009 Jul 15. [Epub ahead of print]. 40. Figueredo VM and Gupta S. Embolic complication of tako-tsubo cardiomyopathy. QJM 2009;102(11):820-2. 41. Figueredo VM. The time has come for physicians to take notice: the impact of psycosocial stressors on the heart. Am J Med. 2009;122(8):704-12. 42. Inamura Y, Miyamae M, Sugioka S, Kaneda K, Okusa C, Onishi A, Domae N, Kotani J, Figueredo VM. Aprotinin abolishes sevoflurane postconditioning by inhibiting nitric oxide production and phosphorylation of protein kinase C-δ and glycogen synthase kinase 3β. Anesthesiology 2009;111(5):1036-43. 43. George A and Figueredo VM. Alcohol and arrhythmias: a comprehensive review. J Cardiovasc Med (Hagerstown). 2010 Apr;11(4):221-8. 44. Maraj S, Figueredo VM, Lynn Morris D. Cocaine and the heart. Clin Cardiol. 2010 May;33(5):264269. 45. Gupta S, Pressman GS, Morris DL, and Figueredo VM. Distribution of left ventricular ejection fraction in angina patients with severe coronary artery disease not amenable to revascularization. Coronary Artery Disease 2010 Aug;21(5):278-80. 46. George A, Arumugham PS, Figueredo VM. aVR – the forgotten lead. Exp Clin Cardiol 2010 Summer;15(2):e36-44. 47. Moinuddin M, Figueredo VM, Amanullah A. Infiltrative Diseases of the Heart: A Systematic Review. Reviews in Cardiovascular Medicine. 2010;in press. 48. Makkuni P, Kotler M, Figueredo VM. Diverticular and aneurysmal structures of the left ventricle in adults. Texas Heart Institute Journal. 2010;in press. 45. Gupta S, Pressman GS, and Figueredo VM. Incidence of, Predictors for, and Mortality Associated with Malignant Ventricular Arrhythmias in Non-ST Elevation Myocardial Infarction Patients. Coronary Artery Disease 2010 Sep 24. [Epub ahead of print]. 46. Figueredo VM, Pressman GS, Romero-Corral A, Murdock E, Holderbach P, Morris DL. Improvement in Left Ventricular Systolic and Diastolic Performance During Ranolazine Treatment in Patients With Stable Angina. J Cardiovasc Pharmacol Ther 2010 Oct 5. [Epub ahead of print]. 10 Figueredo, V.M. Invited Reviews and Book Chapters: 1. Figueredo VM and Weiner MW: Magnetic resonance of the heart. Chapter in Clinical Applications of Magnetic Resonance Spectroscopy, S. Narusa, ed.; Igaku-Shoin LTD, Tokyo; 1991;117-128. 2. Figueredo VM and Camacho SA: Basic mechanisms of myocardial dysfunction: cellular pathophysiology of heart failure. Current Opinion Cardiol 1993; 8:369-375. 3. Amidon TM, Figueredo VM, and Wolfe CL: Thrombolytic therapy in acute myocardial infarction. Hospital Formulary 1993; 28:558-572. 4. Figueredo VM and Camacho SA: Basic mechanisms of myocardial dysfunction: cellular pathophysiology of heart failure. Current Opinion Cardiol 1994;9:272-279. 5. Figueredo VM and Cheitlin M: Risk stratification. Chapter in Management of Acute Myocardial Infarction , Braunwald E and Julian DG, eds., WB Saunders LTD, London, 1994:361-391. 6. Figueredo VM, Amidon TM, and Wolfe CL: Thrombolysis after acute myocardial infarction. Who should be added to inclusion criteria? Postgrad Med 1994;96(8):30-40. 7. Figueredo VM, Amidon TM, and Wolfe CL: Adjuvant therapy with thrombolysis in acute myocardial infarction: antiplatelet agents, antithrombotic agents, and the role of angioplasty. Postgrad Med 1994;96(8):45-54. 8. Figueredo VM and Camacho SA: Basic mechanisms of myocardial dysfunction: cellular pathophysiology of heart failure. Current Opinion Cardiol 1995;10(3):246-252. 9. Pharmacy and Therapeutics Committee, San Francisco Department of Public Health: Guidelines for cost-effective treatment of hypertension in adults. Pharmacy and Therapeutics Forum 1996;44(4,5):1-5. 10. Figueredo VM and Goldschlager N: Ventricular arrhythmias and sudden death in patients with myocardial dysfunction due to myocardial infarction and dilated cardiomyopathy: a clinical perspective. Chapter in Interventional Electrophysiology, Saksena S and Luderitz B, eds., Futura Publishing Co., Inc., New York, 1996;165-184. 11. Figueredo VM: Risk stratification after acute myocardial infarction. Postgrad Med 1996;99(4):207214. 12. Figueredo VM: Alcohol Effects on the Cardiovascular System. Section in the Ninth Special Report to the U.S. Congress on Alcohol and Health from the Secretary of Health and Human Services, U.S. Department of Health and Human Services, June 1997. 13. Figueredo VM and Mochly-Rosen D: Ethanol and signal transduction in the myocardium: implications for the detrimental and beneficial effects. Chapter in Alcohol and the Cardiovascular System, Zakhari S and Wassef M, eds., CSR, Inc., Washington, DC, 1996;263-278. 14. Figueredo VM: The effects of alcohol on the heart: detrimental or beneficial? Postgrad Med 1997;101(2):165-176. 15. Camacho SA and Figueredo VM: Alcohol and the cardiovascular system. Chapter in Cardiology Loose Leaf, Parmley WW and Chatterjee K, eds., Lippincott-Raven Publishers, Philadelphia, 1997;3:121. 16. Figueredo VM: Alcohol Effects on the Cardiovascular System. Section in the Tenth Special Report to the U.S. Congress on Alcohol and Health from the Secretary of Health and Human Services, U.S. Department of Health and Human Services, June 2000. 17. Bishop T and Figueredo VM: Hypertension therapy: Attacking the renin-angiotensin system. Western J Med 2001;175(2):119-124. 18. Miyamae M, Sugioka S, Figueredo VM: Additive cardioprotection by ethanol and sevoflurane: Are sarcolenmal KATP channels also involved? Response to Letter to the Editor. Anesth Analg 2008;106(6):1926-1927. 19. Miyamae M, Kaneda K, Domae N, Figueredo VM. Cardioprotection by regular ethanol consumption: potential mechanisms and clinical application. Curr Drug Abuse Rev. 2010 Mar;3(1):3948. 11 Figueredo, V.M. Abstracts (those which have appeared in manuscript form are not included): 1. Baker AJ, Keung EC, Camacho SA, Figueredo VM, Weiner MW: Slowed myocardial relaxation with high preload is not due to slowed decline of activation. Biophys J 1996; 70:A40. 2. Miyamae M, Rodriguez M, Chang KC, Camacho SA, Mochly-Rosen D, Figueredo VM: Immunolocalization of activated epsilon protein kinase C in isolated adult cardiomyocytes. J Am Coll Cardiol 1997;29(2):345A. 3. Rodriguez MM, Miyamae M, Camacho SA, Diamond I, Mochly-Rosen D, Figueredo VM: Protein kinase C translocation with chronic ethanol exposure: potential mechanism for a chronic cardioprotective effect against reperfusion injury. J Am Coll Cardiol 1998;31(2):448A. 4. Hutchison SJ, Sudhir K, Chou TM, Chatterjee K, Figueredo VM: Nitric oxide-mediated vasodilation (tolerance) to hypertensive effects of ethanol. J Am Coll Cardiol 1998;31(2):262A. 5. Gray MO, Zhou HZ, Dulbecco FL, Figueredo VM, Karliner JS: Mechanisms of cardiac preconditioning in a mouse model of moderate ethanol consumption. FASEB 1999. 6. Beaton SJ, Walker SG, Jaseph M, Boyson C, Brake AD, Dole EJ, Gleeson JM, Gunter MJ, Figueredo VM. Implementation and Evaluation of a Lipid Telemanagement Program. Journal of Managed Care Pharmacy 2002; 8(2):110. 7. Sugioka S, Miyamae M, Domae N, Figueredo VM, Kotani J. Blockade of p38 mitogen activated protein kinase before and during ischemia does not abolish sevoflurane-induced cardiac preconditioning in Guinea Pigs. Annual Meeting Program of American Society of Anesthesiologists. 2004:339:A-708. 8. Figueredo VM. Is Emotional Distress a Cause or Consequence of Chronic Illness? Fifth World Congress on Stress. London, England. 2004. 9. Kaneda K, Miyamae M, Sugioka S, Okusa C, Domae N, Figueredo VM, Kotani J. Sevoflurane Enhances Ethanol-Induced Cardiac Preconditioning Through Mitochondrial KATP channels and Protein Kinase C Activation in Guinea Pig Hearts. Annual Meeting of International Anesthesia Research Society. 2006. 10. Sugioka S, Miyamae M, Okusa C, Kaneda K, Domae N, Figueredo VM, Kotani J. Sevoflurane Preconditioning Does not Diminish Phosphorylation of p38 MAPK and MAPKAPK 2 During Sustained Ischemia. Annual Meeting of American Society of Anesthesiologists. 2006. 11. Scales R, Maes JD, Malott T, Figueredo VM, Ketchens V, Ferguson K, Rollinson D. Lovelace Cardiac Rehabilitation: A guideline to quality programming. Journal of Exercise Physiology (online) 2006;abstract 16;9:2. 12. Kaneda K, Miyamae M, Sugioka S, Okusa C, Inamura Y, Domae N, Figueredo VM, Kotani J. Preconditioning-Like Cardioprotection by Regular Ethanol Consumption Lasts at Least 7 Days After Abstention and is Associated With eNOS Upregulation. J Am Coll Cardiol 2007;49(9A):235A. 13. Okusa C, Miyamae M, Sugiok S, Kaneda K, Domae N, Kotani J, Figueredo VM. Anesthetic Preconditioning by 2% Sevoflurane is Lost within 1 hr After a Brief Exposure in Isolated Guinea Pig Hearts. Annual Meeting of International Anesthesia Research Society. 2007. 14. Figueredo VM. The Time Has Come For Physicians to Take Notice: The Impact of Emotional Stress on the Heart. Sixth World Congress on Stress. Vienna, Austria. 2007. 15. Harralson T; McLaughlin M, Walker R, Polansky M, Figueredo VM. Psychosocial Characteristics and Symptomatology of Patients Presenting to the Hospital with Non-Cardiac Versus Cardiac Chest Pain. Society of Behavioral Medicine's 29th Annual Meeting and Scientific Sessions. March, 2008. 16. Kaneda K, Miyamae M, Sugioka S, Okusa C, Inamura Y, Onishi A, Domae N, Figueredo VM, Kotani J. Persistent Cardioprotection by Regular Ethanol Consumption After Abstention Depends on eNOS but not iNOS Activity After Reperfusion. Circulation. 2008;118:S498. 12 Figueredo, V.M. 17. Gupta S and Figueredo VM. Ventricular Arrhythmias in patients with Non-ST Elevation Myocardial Infarction (NSTEMI): Incidence, Predictors and Mortality. J Am Coll Cardiol 2009;53(10 Suppl A):A316. 18. Purushottam B, Parameswaran AC, Figueredo VM. Prevalence of Dyssynchrony in Obese Subjects With No Known Cardiac Disease Using Velocity Vector Imaging. Circulation 2009;120:S745. 19. Gupta S and Figueredo VM. Effects of Renal Function on Outcomes of Patients with Non-ST Elevation Myocardial Infarction (NSTEMI) Treated with Early Invasive Strategy. Society of Critical Care Medicine's 39th Critical Care Congress. January 2010. 20. Miyamae M, Domae N, Vincent M. Figueredo VM. Protein kinase activation and cardioprotection by regular ethanol consumption and volatile anesthetics. (Oral presentation) BIT Life Science’ 3rd Annual Protein and Peptide Conference, Beijing, China, March 22, 2010. 21. Chebrolu L, Kao CK, Cardona R, Braverman D, Kim J, Pomerantz SC, Figueredo VM. Comparison of enhanced external counter pulsation outcomes in refractory angina patients with and without atrial fibrillation. National American College of Physicians Meeting, Toronto, Canada, 2010. 22. Okusa C, Miyamae M, Domae N, Figueredo VM, Kotani J. Combined pharmaceutical cardiac preconditioning with dipyridamole and sevoflurane or a NO donor. Annual Meeting of American Society of Anesthesiologists. 2010. 23. Arishiro K, Miyamae M, Momota Y, Okusa C, Kotani K, Domae N, Figueredo VM. Remote preconditioning by carotid artery occlusion limits myocardial infarct size: role of MAPK. Annual Meeting of American Society of Anesthesiologists. 2010. 24. Kaneda K, Miyamae M, Sugioka S, Okusa C, Inamura Y, Onishi A, Shiomi M, Domae N, Figueredo VM, Kotani J. Cardioprotection by regular ethanol consumption is mediated through the bradykinin B2 receptor through increased nitric oxide production. Circulation 2010: in press. 13 Figueredo, V.M. Newspaper Articles 1. Figueredo VM. Lower cholesterol levels urged for older adults. Albuquerque Journal (Living Section). June 16, 2002. 2. Figueredo VM. Doctor Offers More on Hormones and Heart Disease. Albuquerque Journal (Mature Life). February 2003. 3. Scales R and Figueredo VM. Heart-Related Diseases are Occurring at Earlier Ages. Albuquerque Journal (Mature Life). March 2004. 14 Figueredo, V.M. CLINICAL TRIALS 1. Valsartan in Acute Myocardial Infarction (VALIANT). Protocol # CVAL489 0108. 1999. Principal Investigator. 2. A Phase II, Randomized, Open-Label, Crossover, Multicenter, Multidose Study of the Safety, Pharmacokinetics and Pharmacodynamics in DMP 754 (Roxifiban) in Combination with Aspirin in Patients with Coronary Artery Disease. Protocol # DMP 754-017. 1999. Principal Investigator. 3. A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the Clinical Efficacy and Tolerability of early Treatment with Simvastatin 40 mg Daily for 30 Days, Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-Treated Acute Coronary Syndrome Patients Who Have Been Randomized to Receive Enoxaparin or Unfractionated Heparin in Conjunction with Aspirin. Protocol # MK-0733 US A2Z. 2000. Co-Investigator. 4. Omipatrilat in Persons with Enhanced Risk of Atherosclerotic Events (OPERA). Protocol CV137056. 2000. Principal Investigator. 5. Omipatrilat Versus Enalapril Randomized Trial of utility in Reducing Events (OVERTURE). Protocol CV137-068. 2000. Principal Investigator. 6. A Multicenter Prospective, Randomized, Double-Blinded, Parallel Group Study Comparing the Effects of Lotrel (5/20mg) to Amlodipine (5mg) and Benazepril (20mg) on Systolic Blood Pressure and Pulse Pressure in Patients with Systolic Hypertension (SELECT). Protocol CCIB002FUS08. 2002. Principal Investigator. 7. A Multicenter, Double Blind, Placebo Controlled Trial to Evaluate the Effect of Extended Release Metoprolol Succinate (Toprol XL) on Cardiac Remodeling in Asymptomatic Heart Failure Patients (NYHA Class I) with Left Ventricular Dysfunction (REVERT). Protocol 276 Astra Zeneca. 2003. Principal Investigator. 8. A Multicenter Prospective, Randomized, Double-Blinded, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg/day When Added to Ongoing Therapy with a Statin Versus Statin Therapy Alone, in Patients with Hypercholesterolemia Who Have Not Reached National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Target LDL-Cholesterol Level. EASE Trial: Ezetimibe Add-On to Statin for Effectiveness Trial. ProtocolMK-0653. 2003. Principal Investigator. 9. A Multicenter, randomized, double-blind, placebo-controlled, parallel group study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo and irbesartan 150 mg in patients with mild-tomoderate essential hypertension. Protocol CSPP100A2201. 2003. Principal Investigator. 10. VERITAS-2: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Assess the Efficiency, Safety, and Tolerability of Tezosentan in Patients with Acute Heart Failure. Protocol AC-051-307. 2003. Principal Investigator. 15 Figueredo, V.M. 11. A 6-week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolemia in Hispanic Subjects. Protocol No. 4522US0007. 2005. Principal Investigator. 12. A 12-Week, Randomized, Open-Label, 3-Arm, Parallel Group, Multicenter, Phase IIIb Study Comparing the Efficacy and Safety of Rosuvastatin 20 mg and 40 mg with that of Atorvastatin 80 mg in Subjects with Acute Coronary Syndromes. Protocol No. 4522US/0001. 2005. Principal Investigator. 13. A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease. Protocol No. CG104. 2008. Principal Investigator. 16
© Copyright 2024